• Citer

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.

par Herbrecht, R;Maertens, J.;Baila, L.;Aoun, Michel ;Heinz, W;Martino, Robert;Schwartz, S.;Ullmann, Andrew;Meert, L;Paesmans, Marianne ;Marchetti, Oscar;Akan, Hamdi;Ameye, Lieveke;Shivaprakash, M;Viscoli, Claudio
Référence Bone marrow transplantation, 45, 7, page (1227-1233)
Publication Publié, 2010-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
Auteur:	Herbrecht, R; Maertens, J.; Baila, L.; Aoun, Michel; Heinz, W; Martino, Robert; Schwartz, S.; Ullmann, Andrew; Meert, L; Paesmans, Marianne; Marchetti, Oscar; Akan, Hamdi; Ameye, Lieveke; Shivaprakash, M; Viscoli, Claudio
Informations sur la publication:	Bone marrow transplantation, 45, 7, page (1227-1233)
Statut de publication:	Publié, 2010-07
Sujet CREF:	Cancérologie
MeSH keywords:	Adult
	Aged
	Antifungal Agents -- therapeutic use
	Aspergillosis -- drug therapy -- mortality
	Drug Therapy, Combination
	Drug Toxicity
	Echinocandins -- administration & dosage -- therapeutic use -- toxicity
	Europe
	Female
	Graft vs Host Disease
	Hematopoietic Stem Cell Transplantation -- adverse effects -- methods -- mortality
	Humans
	Male
	Middle Aged
	Survival Rate
	Transplantation, Homologous
	Treatment Outcome
	Young Adult
Note générale:	Clinical Trial
	Clinical Trial, Phase II
	Journal Article
	Multicenter Study
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0268-3369
	info:doi/10.1038/bmt.2009.334
	info:pii/bmt2009334
	info:scp/77955012411
	info:pmid/20062093